23 results on '"Barrios C."'
Search Results
2. A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).
3. A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).
4. A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC).
5. Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC).
6. Survival analysis of stage IV NSCLC patients treated by the Brazilian public health system compared with patients treated at a research center in the same institution.
7. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).
8. Capecitabine (Cap) monotherapy in anthracycline (A)/taxane (T)-pretreated MBC.
9. Patients’ preferences for adjuvant chemotherapy for breast cancer: What makes it worthwhile in a Latin American population?
10. Hand–foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU).
11. Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).
12. The GOLD reGISTry: A global observational registry collecting longitudinal data on patients with advanced GIST—Second annual summary.
13. A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801.
14. ERCC1 expression and survival in small cell lung cancer
15. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
16. ERCC1 expression is a predictor of clinical outcome in germ cell tumors treated with standard cisplatin based chemotherapy
17. Phase II trial of high dose imatinib in recurrent glioblastoma multiforme (GBM) with platelet derived growth factor receptor (PDGFR) expression
18. Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: Preliminary results of a phase 2 trial
19. Determination of expression of platelet derived growth factor receptors (PDGFR) in astrocitic tumors
20. Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy
21. Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy
22. Phase II study of capecitabine and irinotecan as first-line treatment in metastatic colorectal cancer: First trial of the Brazilian Oncology Consortium (BOC-CRC 001)
23. Phase II study of capecitabine and irinotecan as first-line treatment in metastatic colorectal cancer: First trial of the Brazilian Oncology Consortium (BOC-CRC 001)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.